A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05091567

Recruitment Status : Active, not recruiting

First Posted : October 25, 2021

Last Update Posted : March 12, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Jazz Pharmaceuticals

Information provided by (Responsible Party):

Hoffmann-La Roche

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	April 18, 2025
Estimated Study Completion Date :	March 6, 2026

To Top